Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Biogen
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05688436CT.gov A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | — | Active Not Recruiting | — | — | — |
NCT03232073CT.gov Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | — | Completed | — | — | — |
NCT02907177CT.gov Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) | — | Terminated | — | — | — |
NCT02425644CT.gov Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis | — | Completed | — | — | — |
NCT01093326CT.gov Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT01006265CT.gov Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ponesimod (this asset) | Biogen | P3 | B · 62 |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Fingolimod | Biogen | P4 | BB |
| Natalizumab | Biogen | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Ponesimod
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ponesimod in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ponesimod-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →